Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22902078 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1GLAGAACRBN | |
| SCHEMBL16097822 | 0.75 | — | — | |
| SCHEMBL2755818 | 0.70 | MAPT (0.41) | KDM4EALDH1A1GLAGAACRBN | |
| SCHEMBL22901959 | 0.65 | BRD4 (0.38) | CRBNBRD4CREBBPEP300 | |
| SCHEMBL22902081 | 0.65 | BRD4 (0.38) | CRBNBRD4CREBBPEP300 | |
| SCHEMBL21608159 | 0.64 | MAPT (0.31) | KDM4EALDH1A1CRBNLMNACYP2C19 | |
| SCHEMBL21608091 | 0.64 | MAP3K14 (0.32) | KDM4ECRBNLMNACYP2C19MAPT | |
| SCHEMBL11845142 | 0.64 | MAPT (0.31) | MAPT | |
| SCHEMBL31474209 | 0.64 | KDM4E (0.31) | KDM4ECRBNLMNACYP2C19MAPT | |
| SCHEMBL20614486 | 0.63 | CREBBP (0.52) | CRBNBRD4CREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017332-A1 | ISOMER-ENRICHED 3-CARANLACTAMS AND POLYAMIDES BASED THEREON WITH HIGH OPTICAL PURITY AND ADJUSTABLE CRYSTALLINITY FOR HIGH-PERFORMANCE APPLICATIONS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017332-A1 | ISOMER-ENRICHED 3-CARANLACTAMS AND POLYAMIDES BASED THEREON WITH HIGH OPTICAL PURITY AND ADJUSTABLE CRYSTALLINITY FOR HIGH-PERFORMANCE APPLICATIONS | NOTUM, MGAM, CARM1 | KDM4E 810/4885ALDH1A1 1944/4885GLA 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.